Comparative Pharmacology
Head-to-head clinical analysis: YAZ versus ZOVIA 1 50E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: YAZ versus ZOVIA 1 50E 21.
YAZ vs ZOVIA 1/50E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and drospirenone; suppresses gonadotropins (FSH and LH) inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration. Drospirenone has antimineralocorticoid and antiandrogenic activity.
Combination estrogen-progestin contraceptive: Ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; Norethindrone induces cervical mucus thickening and endometrial thinning, impeding sperm penetration and implantation.
One tablet (0.02 mg ethinyl estradiol and 3 mg drospirenone) orally once daily for 24 days, followed by 2 days of placebo.
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets for 28-day cycle.
None Documented
None Documented
Terminal elimination half-life of drospirenone is 31.2-32.5 hours; ethinyl estradiol: 13-27 hours. Steady-state achieved after 10 days of daily dosing. Clinically, once-daily dosing maintains stable concentrations.
Terminal elimination half-life: 13±3 hours (range 10-20 h) for the progestin component; clinical context: steady-state achieved within 5 days, with minimal accumulation.
Approximately 50% of drospirenone is excreted renally (metabolites, with <10% unchanged), and 50% via feces (biliary) after hepatic conjugation. Ethinyl estradiol is primarily excreted renally (60%) and fecally (40%) as glucuronide and sulfate conjugates.
Renal: ~50% (metabolites); Fecal: ~30% (metabolites); Biliary: minor; Unchanged drug: <1% renal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive